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Tanzania continues to enjoy stability and growth in different sectors similar to other 
countries; however, some challenges persist in the health sector, especially in the 
area of cancer care. The current study aimed at reviewing social economic status 
(SES), as well as factors contributing to the increased burden of breast cancer (BC) 
in Tanzania. The current study reviewed different literature ranging from nationally/
internationally published statistics, academic publications, health information of 
non-governmental organizations, academic researchers, and other sources of health 
information to better understand the socioeconomic and BC care status in Tanzania. 
The current review showed that BC is still the second most prevalent malignant disease 
in Tanzania, and most of the patients referring to medical centers are in the advanced 
stage of the disease due to shortage and unaffordability of health care services. The 
majority of health-related interventions and investments target infectious diseases, 
including HIV-AIDS, tuberculosis, malaria, as well as maternal and child health-related 
conditions, compared to noncommunicable diseases (NCDs) such as BC. In spite of 
some setbacks and improvements in healthcare facilities (e g, novel techniques for early 
detection), the best way to address BC care is affordable fees for clinical and laboratory 
investigations, accessible treatment, palliative care, follow-up, rehabilitative care, and 
better management and allocation of resources.
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The major challenges of breast cancer (BC) care in 
low- and middle-income countries (LMICs) including 
Tanzania are early diagnosis and disease prevention, 
as well as providing the patients with pre- and post-
therapies at effective cost. BC is second to cervical 
cancer (CC) in Tanzania due to its high mortality 
rate, poor survival and the fact that it affects both 
females and males similarly and negatively impacts 
the economically active population. The current 
review study was conducted to understand the status 
of care services directed at this disease in Tanzania. 
Since its independence in the early 1960s, Tanzania 
has continued to maintain socio-political stability 
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providing more support to foreign investors compared 
to its neighboring countries. With an estimated 
population of 52 million, Tanzania’s population 
grows at an annual rate of 2.3%-2.7%, triggering the 
rise in demand for social comforts and infrastructure 
according to the 2012 Population and Housing 
Census [1, 2]. As claimed by the Business Monitoring 
Intelligence and the National Bureau of Statistics, a 
robust economic growth based on the infrastructure 
investment in standard-gauge electrical railways, ports, 
and harbors, as well as expansion and improvement 
of roads are expected to be among the main drivers 
of gross domestic product growth from 2017 to 2026, 
with a constant average of around 6.2% [1, 3]. 
Following the Deloitte Touché Tohmatsu Limited 
report in 2016 and The Citizen Tanzania newspaper 
in 2018, despite the promising implementation and 
growth in telecommunication (via mobile financial 
service), agriculture and industrialization focusing 
on agricultural food processing and employment of 
about 65% of the population [1, 4], certain gaps in 
the public health system still exist, including poor 
water, hygiene, and sanitation as well as health 
care facilities, which may contribute negatively to 
the perceived socio-economic status of the country. 
Due to increased incidence (7.2%) and number of 
deaths occurring each year, BC becomes the second 
major public health concern for women worldwide, 
specifically in Tanzania, which is often diagnosed 
in an advanced stage largely due to lack of reliable 
screening settings, early detection, and thus, making 
it fatal for 56% of the women diagnosed according to 
the Foundation of Cancer Care in Tanzania. Despite 
being the second cause of death among women after 
CC in Tanzania, BC incidence is higher in LMICs, 
where case-fatality rates are disproportionately 
higher. The current study aimed at reviewing the 
current status of BC care in Tanzania, focusing on 
involved socioeconomic factors and identifying 
possible diagnostic and prognostic targets and 
treatment affordability in the country.
For this purpose, a review of the literature was 
conducted on related academic publications, health 
information data of non-government organization/
civil societies, health care institutions, academic 
research, and other health-related sources 
(MEDLINE and Google Scholar), for better 
understanding of BC, socio-economic, and health 
status in Tanzania (Figure 1). 
Figure 1: Assessment of Literature Review
• Press releases 




National Bureau of Statistics 
(NBS) 
•
Ministry of Health, Community 
Development, Gender, Elderly 
and Children (MoHCDGEC) of 
United Republic of Tanzania 
• World Health Organistion 
(WHO) 
• Deloitte 
• World Bank (WB) 
• African Health Observatory 
(AHO)
• Bray et al., (2018) 
• Dumay et al., (2013) 
• Eble et al., (2003) 
• Mabula er al., (2012) 
• Mwakigonja et al., (2016) 



















The healthcare sector funding in Tanzania and 
other LMICs is steadily increased over the years, as 
reflected by the continuous expansion of services, 
as well as the quality of care; although there is 
still plenty of room for further improvement [5], 
including the possibility for increasing healthcare 
spending per capita from about US$44 currently to 
at least US$54, as recommended for the developing 
countries by the high-level Taskforce on Innovative 
International Financing for Health Systems [1, 
6]. Notably, communicable diseases; maternal, 
newborn, and childhood illnesses; other diseases- 
e.g. neglected tropical diseases; noncommunicable 
diseases (NCDs); and malnutrition are among 
the main causes of morbidity and mortality in the 
country [7-10]. Under such circumstances, it is 
therefore desirable that the demand on healthcare 
delivery system at all levels in terms of drugs, 
equipment, and medical supplies be matched with 
a corresponding level of funding, in order to allow 
sustainability in healthcare provision. Such a level 
of funding helps to prevent deterioration of the 
physical health care infrastructure, including public 
utilities (energy, water, and sanitation), and the 
supply of health-related logistics at the healthcare 
facilities, following the African Heath Observatory 
and UNICEF report [6, 11, 12]. Furthermore, the 
availability of requisite funding might support and 
sustain poor healthcare management in addition 
to the regulatory frameworks, wages, and other 
incentives for healthcare workers [13]. Naturally, 
improved funding results in improved health care, 
which subsequently results in a decreased burden 
of disease in the country and ultimately increased 
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productivity [3, 6, 12]. Since women make the 
majority of productive force in LMICs such as 
Tanzania, improved BC care directly and positively 
impacts productivity and economic growth thus 
results in the improved community, as well as 
individual welfare.
Burden of Noncommunicable Diseases
Broadly speaking, there is an evidence of the 
increased global burden of NCDs, particularly 
in developing countries such as Tanzania, 
compared with developed ones -e.g. USA, Eastern 
Mediterranean, and Europe [14, 15]. In Tanzania, 
NCDs, such as cardiovascular diseases, chronic 
respiratory diseases, diabetes, cancer, and injuries, 
are reported as the major public health issues that 
significantly contribute to increased mortality and 
morbidity across all age groups and genders [14, 16] 
(Figure 2 and Figure 3).
Figure 2: Proportion of Mortality in Tanzania
Source: The World Health Organization, 2014. Noncommunicable 
















Figure 3: Proportion of Mortality in Tanzania
Source: The World Health Organization, 2018. Noncommunicable 
















Numerous factors, including modifiable (i.e. 
tobacco use, unhealthy diet, insufficient physical 
activities, alcohol consumption, occupation, etc.) 
and non-modifiable factors (i.e. aging, gender, 
race, and genetic dynamics) contribute to increased 
disease burden [19-21]. Following the World 
Health Organization (WHO) STEPwise approach 
to Surveillance conducted in Tanzania from 2012 to 
2013, statistics showed that 14.1% of the population 
were tobacco smokers, 29.3% were associated with 
alcohol consumption, 26% were overweight and 
hypertensive, and only 2.8% followed a healthy 
diet [22]. As a result, many people spend their non-
standard form of employment revenue for diverse 
healthcare needs. Urgent measures should then be 
taken in order to mitigate the burden of NCDs in 
developing countries including Tanzania [8-10].
Cancer Burden 
Cancer is one of the major life-threatening diseases 
in the world. Globally, BC is the most frequently 
diagnosed malignant disease and the leading cause 
of cancer death among females, accounting for 23% 
of the total cases and 14% of the cancer deaths [16, 
23, 24]. The current report from WHO estimated 
that more than 17 million new cancer cases were 
diagnosed, with more than 9 million accounting for 
death [25]. According to gender, lung cancer (2.1 
million cases) and prostate cancer (1.2 million cases) 
are the first and most common cancers globally 
among males, with more than 1.5 million deaths 
annually. With more than 2 million cancer cases 
among females, the most commonly encountered 
cancers are CC, BC, and colorectal cancer, all being 
responsible for up to 522,000 deaths worldwide every 
year [26, 27]. However, BC was the second cause 
of death among females in Tanzania, following CC 
in 2012, with approximately 2732 (14.4%) newly 
diagnosed cases [28, 29]. Over the years, the status 
of BC disease remained unchanged in Tanzania in 
contrast to developed countries (Figure 4, Figure 
5, and Figure 6). It was partly due to limitations in 
timely screening, early diagnosis, low availability of 
immunohistochemistry (IHC) test for receptor status, 
and lack of cancer registries. The fact that individuals 
still seek traditional health remedies in this part of the 
world instead of conventional medicine increases the 
burden, thus causing delayed diagnosis and treatment, 
as well as underreporting [16, 28, 30-34]. 
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Figure 4: The Incidence of Breast Cancer in Tanzanian and Other 
Races in the US in 2014
























Figure 5: Cancer Incidence in Tanzania in 2012



















Figure 6: Cancer Incidence in Tanzania in 2016
























Most of the time, many diseases, including BC, 
are diagnosed at a late/advanced stage in most 
developing countries, resulting in the inability 
to reduce the frequency and consequences of the 
disease [16, 28, 30-33]. It is thus a challenging, but 
noble and important task to find appropriate strategic 
plans to diagnose (including molecular tests) and 
effectively treat BC, and reduce its incidence [35].
Non-Molecular Breast Cancer Screening Ap-
proaches in Tanzania
Surgery was the predominant and standard 
treatment for BC in the past century until the 
past decade. However, treatment modalities 
underwent drastic changes over the years due 
to novel research discoveries, which include 
elucidation of more prognostic factors, histological 
and immunohistological characterization, and 
cytogenetic diagnosis, leading to a wider range of 
therapeutic options, including customized/targeted 
therapies. Self-examination characterized by a 
palpable mass or lump most frequently located in the 
upper outer quadrant of the breast, nipple discharge, 
peau d’orange, skin ulceration, and fungating mass 
are most often discovered by the patient [37, 38]. 
Besides, mammography screening is one of the 
conventional examination techniques, providing 
information about prognostic factors (tumor size, 
lymph-node involvement, and metastasis) helping 
to classify a patient with benign condition or 
malignancy. Comprehensive molecular profiling of 
tumors is widely studied over the past few years in 
a variety of cancers, leading to the development of a 
new discipline termed “personalized medicine” [34, 
37-39]. 
Molecular Biomarker Screening of Breast Can-
cer in Tanzania
Numbers of proteins and germline markers 
for BC are identified, qualified for clinical 
examination, validated, and reported by the 
National Comprehensive Cancer Network (NCCN) 
for which the targeted drugs are discovered and 
exploited; the proteins include estrogen receptors 
(ER), progesterone (PR), human epidermal receptor 
(HER-2), the BRCA1/2, PIK3CA, PD-L1, and tumor 
suppressor (p53) [40]. Other proteins such as Ki-67 
and anti-apoptotic cell protein (BCL-2) also attracted 
the attention of researchers; although they were 
also studied as potential prognostic markers of BC, 
they are not recommended for clinical assessment 
by NCCN yet. Although many laboratories and 
medical centers do not assess molecular profiles 
of BC, such as ER, PR, and HER-2 as standard 
procedure for patients in Tanzania, studies show the 
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correlation of Ki-67, p53, and BCL-2 with clinical 
presentations of the disease such as histopathology 
grade and prognosis among patients, regardless 
of their low applicability in clinical trials [35, 41-
43]. The p53 is an oncoprotein (also called TP53) 
encoded by p53 tumor suppressor gene that normally 
limits cell growth by monitoring quickly dividing 
cells, restoring inconsistent DNA, and regulating 
apoptosis, but it is also a key prognostic marker in 
the early detection of BC [35, 44, 45]. Moreover, 
BCL-2, on the other end, is an anti-apoptotic 
cell protein encoded by the BCL-2 gene with an 
imperative effect on cell survival through inhibiting 
the pro-apoptotic antigen activity. The BCL-2 is also 
associated with hormone receptor status due to its 
manifestation in normal breast glandular epithelium 
and upregulation by estrogen [46-48]. Besides, Ki-
67, p53, and BCL-2 are the most significant and 
helpful predictive variables presently accessible for 
endocrine treatment targets [35, 43, 49, 50]. Further 
studies and investigations on molecular markers 
are required for therapeutic success. This can only 
be sustained through the strengthening of clinical 
settings, as well as laboratory facilities and services, 
leading to effective treatment.
Breast Cancer Diagnosis and Treatment Services 
in Tanzania
BC screening and diagnosis involve self-
observation, physical examination by a physician, 
breast ultrasonography, mammography, FNAB/
FNAC, and core-needle biopsy (or incisional biopsy 
where cores are not available), as well as chest 
radiography to rule out metastasis once the cancer 
is confirmed [51]. In addition, where the core-
needle biopsy is not available and patients do not 
express or respond to endocrine therapy, FNAC 
smears coupled with cell blocks as well as more 
target molecular markers could have a comparable 
diagnostic value in addition to their economic 
advantages. Most often, the treatment and diagnosis 
of BC require multiple healthcare facilities and 
professionals- i.e., clinicians (surgeons, oncologists, 
and others), ultra-sonographers, radiographers, 
radiologists, pathologists or cytologists, histo-
technologists, cytotechnologists, or a general lab 
scientist as an alternative [32, 52, 53]. These highly-
skilled professionals might not be readily available 
and accessible to many individuals in need of BC 
diagnostic services in LMICs. Some of the laboratory 
procedures are available in Tanzania, including 
fine-needle aspiration biopsy / cytology (FNAB/
FNAC) and core-needle biopsy utilized for tissue 
microarrays (TMAs). These methods need to be 
optimized to allow early and accurate BC diagnosis 
in more medical centers [54, 55]. Moreover, the 
routine IHC test for BC receptors at molecular levels 
(ER, PR, and HER2) used as the most early, rapid, 
accurate, and cost-effective diagnostic measure for 
BC is currently available at the Histopathology Unit 
of the Central Pathology Laboratory of Muhimbili 
National Hospital (MNH) in Dar es Salaam [29, 33, 
35]. However, there are only about five regions in 
Tanzania that currently have at least one pathologist 
as well as surgical pathology/cytology services [32].
The current practice to treat BC in Tanzania 
depends on the stage of the disease and includes 
neoadjuvant therapy, followed by mastectomy or 
mastectomy with adjuvant therapy [51]. Patients 
destined to experience recurrence can be candidates 
for systemic adjuvant therapy, and the ones who 
are not at the risk of recurrence do not require 
adjuvant therapy, which is cost-effective to the 
health system. Such decisions are made by the 
specialists of both MNH and Ocean Road Cancer 
Institute (ORCI) through a multidisciplinary tumor 
board. Patients with BC are generally categorized as 
premenopausal and postmenopausal. However, both 
categories are treated with surgery, chemotherapy, 
radiotherapy, and hormonal therapy [tamoxifen-α 
selective estrogen receptor modulator (SERM)], 
depending on the stage of the disease and expression 
level of hormone receptors (HR) [16, 30, 35, 51, 
56]. On the other hand, for postmenopausal women 
not responsive to tamoxifen (an anti-HR drug), 
an aromatase inhibitor (AI) drug (Anastrozole) is 
currently prescribed at MNH alongside surgery 
and chemotherapy. Radiotherapy is given as well 
when surgical margins and regional lymph nodes 
are positive for tumor. Other forms of hormonal 
manipulation, including selective estrogen receptor 
degrader (SERD like fulvestrant) and luteinizing 
hormone-releasing hormone (LHRH) analogs such 
as zoladex are not yet used to treat BC in MNH, 
although zoladex is currently used to treat prostate 
cancer. However, the medical fraternity in MNH 
should also consider the possibility of adding zoladex 
just like anastrozole to tamoxifen non-responders, 
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as it is already available locally. In addition, patients 
strongly overexpressing the HER2 marker may 
be eligible for receiving an immunotherapeutic 
monoclonal antibody agent such as trastuzumab or 
herceptin as well.
Tanzania is one of the few countries in the Eastern, 
Central, and Southern African sub-region that has a 
well-established and longstanding cancer treatment 
institute, named ORCI. Furthermore, new and 
upcoming oncology centers are at different stages 
of the establishment at Bugando Medical Center 
(BMC) in Mwanza, as well as the Kilimanjaro 
Christian Medical Center (KCMC) in Moshi; 
although they may not be still sufficient to serve 
the whole Tanzanian population, majority of those 
may also be rural-based [32, 52]. Nevertheless, this 
is no small feat including the fact that these centers 
serve the neighboring countries. This situation 
makes cancer diagnosis and therapy still expensive 
for many ordinary Tanzanians. Patients with BC in 
the lake regions (around Mwanza) are relatively 
younger premenopausal women mostly referring to 
medical centers at advanced stage of the disease and 
high rate of lymph-node metastasis [57]. Altogether, 
this makes BC care (including cancer diagnosis 
generally) a complex, multistep, and multicentric 
practice, with subsequent high-cost implications to 
the patient and/or his/her family and the country 
as a whole. This may be economically prohibitive 
to the underprivileged patient. Hospital-seeking 
behavior is also determined by the educational 
and socioeconomic status of the patient and/or his/
her family. Consequently, a significant number of 
patients seek traditional remedies/healers only or 
prior to consulting conventional medicine, resulting 
in delayed diagnosis, advanced stage of the disease 
at diagnosis, and poor outcome of treatment. There 
is a need therefore to improve public awareness 
on BC, including setting up screening centers to 
promote early detection and thus allowing timely 
intervention [16, 31, 32, 58].
Limited Access to Breast Cancer Care and Tu-
mor Markers Testing in Tanzania
One of the constraints on BC diagnosis in Tanzania 
is the molecular characterization of tumor markers 
in patients. Several investigations put forward that 
African BC is largely caused by overexpression 
of hormone receptors [59]. Pathologists and 
researchers working in low-resource countries 
face challenges with regard to Standard Operating 
Procedures (SOPs) for IHC staining due to many 
reasons, including outperformance of surgery, pre-
treatment of tissue samples, low-quality specimens 
from large and necrotic tumors, doubtful quality 
of fixative materials, a lengthy stay in the fixative 
agent (regularly for several weeks), poor laboratory 
techniques and low-quality assurance/quality control 
practices, which often lead to the inapplicability of 
advanced IHC techniques [60]. In Tanzania, there is 
a small number of studies on BC diagnosis using 
IHC or other techniques for the assessment of BC 
molecular markers such as Ki-67, p53, and BCL-
2 [31, 33, 35, 61]. In total, there are 169 district 
hospitals and 30 regional referral hospitals in which 
four are public referral and zonal hospitals including 
MNH for the coastal zone, Mbeya Referral Hospital 
in the Southern highlands zone, BMC in the 
lake zone, and KCMC in the Northern zone [32]. 
Unfortunately, not all healthcare activities related 
to BC care are conducted as planned, since most of 
them face limited human resources and poor supply 
of important health commodities. The four public 
referral and zonal hospitals, as well as Aga Khan 
Hospital (AGH), are the most prominent medical 
centers offering cancer screening and diagnostic 
services. However, chemotherapy and palliative 
therapy are only offered by ORCI. Moreover, most 
of these centers lack diagnostic facilities such as 
the IHC technique. All patients with cancer in the 
regional and peripheral zones are directed to MNH 
for hormonal receptors and Her-2 examination or 
other IHC tests. This institution offers an original 
assessment of BC categories in Tanzania, where 
they lack a population-based registry [30, 32]. This 
limitation on facilities with IHC capacity calls for 
government efforts to provide IHC facilities to 
the abovementioned centers. Burson et al., (2010) 
performed a two-year survey in Tanzania using 
medical records of patients with BC admitted to ORCI 
from July 2007 to June 2009. Their results revealed 
that the frequency or molecular characteristics of BC 
in Tanzania are scarcely understood [30]. The MNH 
provides radio- and chemo-therapy for patients 
with BC in partnership with ORCI. However, this 
collaboration offers an extremely specific treatment 
in both overcrowded clinics with long waiting times 
for critical practices such as surgery and pathological 
assessment [32], making treatment outcomes hardly 
sensitive. Improvement of healthcare facilities 
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for early diagnosis and management of cancer is 
therefore imperative.
A study in 2017 by the Ministry of Health, Community 
Development, Gender, Elderly, and Children 
(MoHCDGEC) of Tanzania showed that the fraction 
of patients with BC expressing hormone receptors 
in the various medical center could be substantial 
and significantly affected by therapeutic plans 
(endocrine therapy) [32]. But the current queries are: 
if patients are not substantial for endocrine therapy, 
how are other prognostic biomarkers, such as Ki-67, 
p53, and BCL-2, expressed vis-à-vis the age, stage, 
and grade in patients with BC in these specialized 
hospitals? Is there any correlation between the 
expression of these biomarkers and clinical and 
histopathological features of BC cases admitted 
to MNH? These further questions were partly 
addressed in a research study conducted by Mansouri 
et al., (2019), where a significant association among 
biomarkers (Ki-67, p53, and BCL-2) expression and 
clinico-histopathological features (age, tumor grade, 
stage of the disease, tumor size, and lymph-node 
status) of BC were observed [35]. However, further 
studies are required to comprehensively elucidate 
the association of BC biomarkers, the pathogenesis, 
histopathology, prognosis and therapeutic options to 
improve patient care and wellbeing and positively 
enhance the socioeconomic status of patients, the 
community and country as a whole. Furthermore, 
the future of BC care in developing countries 
should include targeted therapeutic modalities 
based on cytogenetics and other ancillary molecular 
diagnostics, including gene microarrays [7, 62]. 
These might serve as the second frontline in the 
quest for improved care and outcome of patients 
with BC in Tanzania. 
CONCLUSIONS
BC is still a global public health concern, but mostly 
in developing countries such as Tanzania where a 
significant proportion of the population may also be 
affected by poverty and limitations in availability, 
accessibility, and affordability of appropriate 
healthcare services. The healthcare system of the 
country needs to be strengthened particularly in 
the area of cancer diagnosis and care. To positively 
affect the survival of patients with BC through 
personalized therapy systems, BC management 
in Tanzania should discover routes to improve the 
pathology facilities, including IHC for screening 
biomarkers in a regular cancer management process. 
The increased investments in the healthcare system, 
including novel and pre-existing techniques for 
early detection of BC and other cancers, affordable 
laboratory diagnostic fees for patients, availability 
of comprehensive and customized treatment 
modalities and palliative care, improved patient 
follow-up and management, and generally the 
allocation of resources could be the best way to 
tackle this particular health challenge and improve 
the quality of life of patients and thus positively 
affect the productivity. 
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